Get the Stockscreener App
9.52
4.27%
0.39
After Hours:
9.53
0.010
+0.11%
Seres Therapeutics Inc stock is traded at $9.52, with a volume of 50,638.
It is up +4.27% in the last 24 hours and down -28.96% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$9.13
Open:
$9.07
24h Volume:
50,638
Relative Volume:
0.66
Market Cap:
$86.12M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-476.00
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
+7.21%
1M Performance:
-28.96%
6M Performance:
-50.83%
1Y Performance:
-37.77%
1-Day Range:
$8.96
$9.60
1-Week Range:
$8.56
$9.60
52-Week Range:
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
9.52 | 82.59M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday - MarketBeat
Human Microbiome Therapeutics Market to Reach US$ 5.86 Billion - openPR.com
MCRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seres Therapeutics Announces Executive Leadership Changes and Promotions - The Globe and Mail
MCRB: Leadership transition and pipeline progress position the company for key clinical milestones in 2026 - TradingView
[8-K] Seres Therapeutics, Inc. Reports Material Event | MCRB SEC FilingForm 8-K - Stock Titan
Seres Therapeutics, Inc. Announces Executive and Management Changes - marketscreener.com
US Stocks Recap: Does Seres Therapeutics Inc have declining or rising EPSWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Panic Selling: How does Seres Therapeutics Inc perform in inflationary periodsJuly 2025 Reactions & Entry Point Confirmation Signals - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageWhat's Next? - MarketBeat
MCRB Technical Analysis & ETF Price Forecast - Intellectia AI
Layoff Tracker: Viatris Will Cut up to 10% of Global Workforce Over 3 Years - BioSpace
Setup Watch: Can Seres Therapeutics Inc outperform under higher oil prices2025 Big Picture & Consistent Growth Stock Picks - baoquankhu1.vn
Seres down after pausing investments for lead program - MSN
Seres Therapeutics (MCRB) officer trades RSU shares under 10b5-1 plan - Stock Titan
Market Review: Will Seres Therapeutics Inc benefit from green energy policiesQuarterly Portfolio Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
$3.25+ Bn Human Microbiome Market Trends and Global Forecasts, 2035, Driven by Advancements in Microbiome Sequencing, Rising Investments in R&D, and Increasing Demand for Personalized Medicine - GlobeNewswire Inc.
Will Seres Therapeutics Inc. benefit from green energy policiesJuly 2025 Catalysts & Real-Time Buy Zone Alerts - mfd.ru
Is Seres Therapeutics Inc. stock a good choice for value investorsMarket Trend Review & Real-Time Volume Trigger Notifications - mfd.ru
Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MCRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Seres Therapeutics Status update Earnings Call Transcript - MarketBeat
Seres Pauses SER-155 Phase 2 Study, Cuts Costs - marketscreener.com
Seres Therapeutics Pauses SER-155 Investment, Cuts Workforce by 30% - Intellectia AI
Seres Therapeutics Stock Declines Amid Strategic Shift - Intellectia AI
Seres provides program and corporate updates and prioritizes emerging programs in inflammatory & immune diseases - marketscreener.com
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics pauses work on lead drug program amid cash crunch - The Business Journals
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash - Bitget
Seres Shares Down After Co Pauses Drug Development, Lays Off Workers - marketscreener.com
Seres stock falls after pausing Phase 2 study and cutting workforce by 30% By Investing.com - Investing.com Nigeria
Seres stock falls after pausing Phase 2 study and cutting workforce by 30% - Investing.com UK
Biopharmaceutical company Seres Therapeutics, Inc. recently announced the implementation of a series of strategic adjustments aimed at extending its corporate operating cycle. - Bitget
Seres Provides Program and Corporate Updates and - GlobeNewswire
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell? - Defense World
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving AverageTime to Sell? - MarketBeat
Can Seres Therapeutics Inc. stock beat market expectations this quarterLong Setup & Precise Swing Trade Alerts - mfd.ru
Seres Therapeutics announces leadership transition - MSN
Trading Recap: Should I invest in Seres Therapeutics Inc before earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - baoquankhu1.vn
Seres Therapeutics: Strong SER-155 Data, But Dilution Risk Now Warrants A 'Hold' - Seeking Alpha
Microbiome Therapeutics for Patients and PhysiciansMedical / Health Care - Environmental XPRT
Dividend Watch: How does Seres Therapeutics Inc perform in inflationary periods2025 Performance Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Investment Review: How does Seres Therapeutics Inc perform in inflationary periods2025 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average – Should You Sell? - Defense World
Institution Moves: How does ALEX perform in inflationary periodsJuly 2025 Selloffs & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Analyst Calls: Can Seres Therapeutics Inc weather a recessionMarket Growth Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell? - Defense World
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving AverageTime to Sell? - MarketBeat
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):